Did the excitement over CAR T-cell therapies news live up to expectations? What new myeloma drugs and treatment paradigms are now on the horizon? Dr. Brian G.M. Durie explains the most significant findings presented at the 59th American Society of Hematology annual conference for patients, caregivers, and other members of the myeloma community. 


Educational grant provided by: 
Amgen, Celgene , Janssen Oncology,  and Takeda Oncology

 

 

Previous Post
Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone Induces a High Response Rate in Patients with Relapsed MM
Next Post
ASH17: Frontline Options

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.